Grufity logo
Grufity logo

Latest SILVERARC CAPITAL MANAGEMENT, LLC Stock Portfolio

$979Million– No. of Holdings #67

SILVERARC CAPITAL MANAGEMENT, LLC Performance:
2026 Q1: 8.64%YTD: 8.64%2025: 53.51%
Performance for 2026 Q1 is 8.64%, and YTD is 8.64%, and 2025 is 53.51%.

About SILVERARC CAPITAL MANAGEMENT, LLC and 13F Hedge Fund Stock Holdings

SILVERARC CAPITAL MANAGEMENT, LLC is a hedge fund based in Boston, MA. On 2026-05-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, SILVERARC CAPITAL MANAGEMENT, LLC reported an equity portfolio of $979.8 Millions as of 31 Mar, 2026.

The top stock holdings of SILVERARC CAPITAL MANAGEMENT, LLC are KALV, , COGT. The fund has invested 5.9% of it's portfolio in KALVISTA PHARMACEUTICALS INC and 5.6% of portfolio in DIANTHUS THERAPEUTICS INC.

The fund managers got completely rid off VIRIDIAN THERAPEUTICS INC (VRDN), PFIZER INC (PFE) and AVALO THERAPEUTICS INC (AVTX) stocks. They significantly reduced their stock positions in AARDVARK THERAPEUTICS INC, VERACYTE INC (VCYT) and INSMED INC (INSM). SILVERARC CAPITAL MANAGEMENT, LLC opened new stock positions in ZENAS BIOPHARMA INC, SCHOLAR ROCK HLDG CORP (SRRK) and ALKERMES PLC (ALKS). The fund showed a lot of confidence in some stocks as they added substantially to ASCENDIS PHARMA A/S (ASND), RHYTHM PHARMACEUTICALS INC (RYTM) and IBIO INC (IBIO).
SILVERARC CAPITAL MANAGEMENT, LLC Equity Portfolio Value
Last Reported on: 14 May, 2026

SILVERARC CAPITAL MANAGEMENT, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that SILVERARC CAPITAL MANAGEMENT, LLC made a return of 8.64% in the last quarter. In trailing 12 months, it's portfolio return was 77.1%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
zenas biopharma inc22,207,500
scholar rock hldg corp16,695,400
alkermes plc16,276,700
disc medicine inc12,534,000
helix acquisition corp iii12,283,300
xenon pharmaceuticals inc11,499,700
immunovant inc10,289,600
savara inc7,813,160
New stocks bought by SILVERARC CAPITAL MANAGEMENT, LLC

Additions

Ticker% Inc.
ascendis pharma a/s153
rhythm pharmaceuticals inc125
ibio inc113
monte rosa therapeutics inc94.55
immunome inc64.29
erasca inc40.55
syndax pharmaceuticals inc38.28
kalvista pharmaceuticals inc18.51
Additions to existing portfolio by SILVERARC CAPITAL MANAGEMENT, LLC

Reductions

Ticker% Reduced
aardvark therapeutics inc-88.92
fractyl health inc-82.71
cg oncology inc-53.94
adagio med hldgs inc-51.11
veracyte inc-49.74
insmed inc-49.69
biogen inc-32.42
abivax sa-28.34
SILVERARC CAPITAL MANAGEMENT, LLC reduced stake in above stock

Sold off

Ticker$ Sold
gossamer bio inc-6,620,740
lexeo therapeutics inc-6,132,850
avalo therapeutics inc-9,523,760
amylyx pharmaceuticals inc-6,115,400
pfizer inc-10,436,400
relay therapeutics inc-3,368,490
cytomx therapeutics inc-1,644,250
x4 pharmaceuticals inc-1,429,550
SILVERARC CAPITAL MANAGEMENT, LLC got rid off the above stocks

Sector Distribution

SILVERARC CAPITAL MANAGEMENT, LLC has about 75.1% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare75.1
Others24.9

Market Cap. Distribution

SILVERARC CAPITAL MANAGEMENT, LLC has about 2.9% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • SMALL-CAP
  • UNALLOCATED
  • LARGE-CAP
  • MICRO-CAP
Category%
MID-CAP41.3
SMALL-CAP28.2
UNALLOCATED24.6
LARGE-CAP2.9
MICRO-CAP2.6

Stocks belong to which Index?

About 58.9% of the stocks held by SILVERARC CAPITAL MANAGEMENT, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
  • S&P 500
Index%
RUSSELL 200057.8
Others41.1
S&P 5001.1
Top 5 Winners (%)%
ERAS
erasca inc
193.3 %
dianthus therapeutics inc
97.0 %
CNTA
centessa pharmaceuticals plc
58.0 %
ORIC
oric pharmaceuticals inc
54.5 %
AGLE
spyre therapeutics inc
53.8 %
Top 5 Winners ($)$
dianthus therapeutics inc
30.0 M
ERAS
erasca inc
19.7 M
KALV
kalvista pharmaceuticals inc
10.6 M
KOD
kodiak sciences inc
10.2 M
cg oncology inc
6.9 M
Top 5 Losers (%)%
fractyl health inc
-46.4 %
TELA
tela bio inc
-44.0 %
aardvark therapeutics inc
-39.6 %
FULC
fulcrum therapeutics inc
-31.5 %
NXTC
nextcure inc
-24.7 %
Top 5 Losers ($)$
fractyl health inc
-10.1 M
URGN
urogen pharma ltd
-8.8 M
abivax sa
-8.5 M
RYTM
rhythm pharmaceuticals inc
-4.4 M
VCYT
veracyte inc
-2.7 M

SILVERARC CAPITAL MANAGEMENT, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SILVERARC CAPITAL MANAGEMENT, LLC

SILVERARC CAPITAL MANAGEMENT, LLC has 67 stocks in it's portfolio. About 42.4% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for SILVERARC CAPITAL MANAGEMENT, LLC last quarter.

Last Reported on: 14 May, 2026
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions